Instead, trastuzumab VL Q89A challenges the theory where high antigen-binding affinity is usually considered as a sign of a functional and efficacious antibody.42,60,61 Here, this mutation retained antigen-binding, but abrogated the antibody’s ability to inhibit HER2+ cancer cell proliferation and induce ADCC. Here, ERBB2 is linked to cancer.